ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/haematology/lymphoid-leukaemias
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Lymphoid leukaemias
44
trial(s) found.
NCT07109219
Paed
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia (
ALLight
)
anti-CD22 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06973187
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (
2025-522860-34-00--BGB-16673-304
)
BTK PROTAC degrader
BTK inhibitor
Chronic lymphocytic leukaemia
Small Lymphocytic Lymphoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06943872
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
2024-517131-52-00--BGB-11417-303
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06876662
Haem
Phase 4
Recruiting
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma (
2024-517760-29-00--27289
)
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06876649
Paed
Phase 4
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06846671
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors (
CaDAnCe-302
)
BTK PROTAC degrader
Bcl2 inhibitor
PI3K delta inhibitor
alkylating agent
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4350 - Toowoomba - ICON Cancer Centre Toowoomba
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06812715
Haem
Phase 2
Recruiting
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib (
PIPOZA
)
BTK inhibitor
Chronic lymphocytic leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
NCT06588478
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor (
2024-515689-15-01--18877
)
BTK inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Glandore - Ashford Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06564038
Haem
Phase 1
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06528301
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies (
UB-VV111-01
)
gene therapy,CAR-T-cell generating,CD19-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3066 - Epping - Northern Hospital
NCT06514794
Paed
Phase 2
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex) (
WUC007-03
)
allogeneic CAR-T-cell therapy,CD7-targeting
Lymphoma
T-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
NCT06428019
Haem
Phase 3
Recruiting
A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL (
2024-512147-23-00--M24-287
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT06395103
Paed
Phase 1 / Phase 2
Recruiting
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (
9999-01A
)
anti-ROR1 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
Burkitt lymphoma
Diffuse large B-cell lymphoma
Ewing sarcoma
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06137118
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (
SYRUS
)
bispecific T-cell engager,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06136559
Haem
Phase 3
Recruiting
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (
2022-501697-19-00--1026-011
)
BTK inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NCT06124157
Paed
Phase 3
Recruiting
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (
NCI-2023-09214
)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05947851
Haem
Phase 3
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010) (
MK-1026-010--1026-010
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05643742
Haem
Phase 1
Recruiting
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (
CRSP-ONC-006
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05618028
Haem
Phase 1
Recruiting
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies (
2022-503136-13--M23-324
)
MALT1 inhibitor
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
NCT05512390
Haem
Phase 1
Recruiting
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies (
M22-716
)
anti-CD19 antibody-drug conjugate,glucocorticoid receptor modulator
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05327894
Paed
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.8011 - Christchurch - Christchurch Children's Hospital
NCT05254743
Haem
Phase 3
Recruiting
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
BRUIN-CLL-314
)
BTK inhibitor
Chronic lymphocytic leukaemia
Leukaemia
Small Lymphocytic Lymphoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT05091424
Haem
Phase 1
Recruiting
A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (
BO43243
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05006716
Haem
Phase 1
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies (
CaDAnCe-101
)
BTK PROTAC degrader
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
Waldenström Macroglobulinemia
NSW
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04994717
Haem
Phase 3
Recruiting
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study) (
2023-503640-14--20190360
)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04895436
Haem
Phase 2
Recruiting
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia (
ReVenG
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04811560
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (
cAMeLot-1
)
KMT2A inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Leukaemia
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04728893
Haem
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (
MK-1026-003--1026-003
)
BTK inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Small lymphocytic lymphoma
Waldenström Macroglobulinaemia
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04521231
Haem
Phase 1
Recruiting
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL (
2023-506136-32--20180257
)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04065399
Haem
Phase 1
Recruiting
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation (
AUGMENT-101
)
menin-MLL1 inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Leukaemia
Mixed phenotype acute leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT03959085
Haem
Phase 3
Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (
NCI-2019-02845--AALL1732
)
anti-CD22 antibody-drug conjugate
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Leukaemia
Mixed phenotype acute leukaemia
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03666000
Haem
Phase 1
Recruiting
Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (azercabtagene Zapreleucel or "azer-cel") in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and R/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (
PBCAR0191-01
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
Non-Hodgkin's lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03601442
Paed
Available
Managed Access Program (MAP) Cohort Treatment Plan
CCTL019B2003I
to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)
autologous CAR-T-cell therapy,CD19-targeting
Acute lymphoblastic leukaemia
Diffuse large B-cell lymphoma
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT03590171
Paed
Phase 2
Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group (
IntReALL-HR-2010
)
Bortezomib
cancer therapy
cancer therapy,proteasome-targeting
proteasome inhibitor
Acute lymphoblastic leukaemia
VIC
3168 - Clayton - Monash Medical Centre
NCT02966756
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
M14-728
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT02670564
Paed
Phase 4
Recruiting
Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) (
NZ-2015-069--ZH-2014-0535
)
Busulfan
Treosulfan
alkylating agent
cancer therapy
cytotoxic chemotherapy
Acute lymphoblastic leukaemia
ACTRN12625000965404
Haem
Phase 3
Not yet recruiting
ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (
CLL-RT2
)
BTK inhibitor
bispecific T-cell engager,CD20-targeting
Cancer
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma,Richter's transformation
ACTRN12625000732482
Haem
Phase 2
Not yet recruiting
CLL12 - An ALLG phase II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (
AETHER-trial
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
ACTRN12625000387426
Haem
Phase 2
Not yet recruiting
CLL11 - An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab (
MOONSHOT
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
ACTRN12624001142527
Haem
Phase 4
Not yet recruiting
Safety analysis of 90-minute Obinutuzumab infusion in Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL) patients (
nil
)
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Follicular lymphoma
QLD
4870 - Cairns - Cairns Base Hospital
ACTRN12623000640606
Haem
Phase 2
Recruiting
CLL08 - A phase 2 study of venetoclax/rituximab (VenR) re-treatment in relapsed/refractory CLL patients with disease progression following VenR as their last line of therapy
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
ACTRN12622001232729
Radonc
Phase 2
Recruiting
A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (
The-ANZHIT-2-study
)
Cyclophosphamide
Fludarabine
Mesna
Radiotherapy
Treosulfan
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
sodium mercaptoethanesulfonate
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Chronic myelogenous leukaemia
Myelodysplastic syndrome
Myeloproliferative Neoplasm
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12622000308796
Haem
Phase 1
Recruiting
A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (
VICTORY-study
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Leukaemia
Lymphoma
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
ACTRN12619000079145
Haem
Phase 1
Not yet recruiting
A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (
The-AutoCAR19-Trial
)
Cyclophosphamide
Fludarabine
Radiotherapy
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6000 - Perth - Royal Perth Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (38)
Not yet recruiting (5)
Recruitment Country and State
VIC (32)
NSW (21)
WA (20)
QLD (16)
SA (13)
NZ (8)
TAS (1)
ACT (1)
Phase
Phase 1 (12)
Phase 1 / Phase 2 (4)
Phase 2 (11)
Phase 3 (12)
Phase 4 (4)
Trial Type
Haem (32)
Paed (11)
Radonc (1)
Cancer Therapy Class
BTK
32%
Bcl2
27%
CD20
27%
CD19
25%
CD22
5%
KMT2A
5%
PI3K delta
2%
CAR-T-cell generating,CD19
2%
CD7
2%
ROR1
2%
BCR-ABL1
2%
KIT
2%
PDGFRA
2%
SRC
2%
YES1
2%
MALT1
2%
IL-6
2%
menin-MLL1
2%
menin
2%
proteasome
2%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (13)
3004 - Melbourne, Southbank - Alfred Health (11)
3168 - Clayton - Monash Medical Centre (10)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (8)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (7)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (6)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (6)
4102 - Woolloongabba - Princess Alexandra Hospital (5)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (5)
2139 - Concord - Concord Repatriation General Hospital (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
5042 - Bedford Park - Flinders Medical Centre (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
3066 - Epping - Northern Hospital (3)
6000 - Perth - Royal Perth Hospital (3)
4101 - South Brisbane - Queensland Children's Hospital (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2170 - Liverpool - Liverpool Hospital (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
4575 - Birtinya - Sunshine Coast University Hospital (2)
2217 - Kogarah - St George Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
3052 - Parkville - Royal Children's Hospital Melbourne (2)
2031 - Randwick - Sydney Children's Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
6009 - Perth - Perth Children's Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2480 - Lismore - Lismore Base Hospital (1)
6168 - Cooloongup - Rockingham Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
4350 - Toowoomba - ICON Cancer Centre Toowoomba (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
5037 - Glandore - Ashford Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3168 - Clayton - Monash Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
NZ.8011 - Christchurch - Christchurch Children's Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
2605 - Garran - The Canberra Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Lymphoid leukaemia
B-cell malignancy
Mature B-cell malignancy
Lymphoma
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
B-cell lymphoma
Acute lymphoblastic leukaemia
Small lymphocytic lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
B-cell acute lymphoblastic leukaemia/lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Mixed phenotype acute leukaemia
Acute myeloid leukaemia
Myeloid leukaemia
Waldenström Macroglobulinaemia
Myelodysplastic syndrome
Myeloproliferative neoplasm
T-cell acute lymphoblastic leukaemia/lymphoma
Bone cancer
Burkitt lymphoma
Ewing family of tumours
Ewing sarcoma
Neuroblastic tumour
Neuroblastoma
Neurological cancer
Peripheral nervous system tumour
Primitive neuroectodermal tumour
Sarcoma
Solid tumour
Diffuse large B-cell lymphoma,Richter's transformation
Chronic leukaemia
Chronic myelogenous leukaemia
Multiple myeloma
Plasma cell disorder
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy